At present, Denosumab, an FDA-approved monoclonal antibody targeting RANKL, has demonstrated effectiveness in long-term clinical treatment of osteoporosis without increasing the risk of cancer, infection, cardiovascular diseases, delayed fracture healing, or hypocalcemia (Bone et al., 2017). This evidence concerns the gene TNFSF11 and infection.